Table 2.
Laboratory results and HBV management among participants with HBsAg and receiving work-up (n=27).
| Laboratory results | n | % |
|---|---|---|
|
| ||
| HBeAg present | 9 | 33.3% |
| HBV DNA detectable | 26 | 96.3% |
| Median HBV DNA viral load (IQR) | 2 215 (251 – 254 895) | |
| HBV DNA < 2000 IU/mL | 8 | 29.6% |
| HBV DNA 2000 – 20 000 IU/mL | 14 | 51.9% |
| HBV DNA > 20 000 IU/mL | 5 | 18.5% |
| ALT > ULN (41 IU/L) | 7 | 25.9% |
| APRI ≥ 0.65 | 2 | 7.4% |
| Median APRI (IQR) | 0.24 (0.17 – 0.39) | |
| AFP > upper limit of normal (8.8 ug/L) | 3 | 11.1% |
| Median AFP (IQR) | 2.7 (2.0 – 6.4) | |
|
| ||
| HBV management | ||
|
| ||
| Monitored (HBV mono-infection) | 13 | 48.1% |
| HBV DNA undetectable; ALT <ULN; APRI < 0.65 | 1 | 7,7% |
| HBV DNA 2000 – 20000; ALT <ULN; APRI < 0.65 | 8 | 61.5% |
| HBV DNA >20000; ALT <ULN; APRI < 0.65 | 3 | 23.1% |
| HBV DNA 2000 – 20000; ALT >ULN; APRI < 0.65 | 1 | 7,7% |
| Released before management plan could be finalised | 2 | 7.4% |
| HBV DNA < 2000; ALT >ULN; APRI < 0.65 | 1 | 50.% |
| HBV DNA 2000 – 20000; ALT <ULN; APRI < 0.65 | 1 | 50.% |
| Received treatment for HBV | 12 | 44.4% |
| Tenofovir/emtricitabine for HBV mono-infection | 4 | 33.3% |
| HBV DNA <2000, ALT <ULN & APRI < 0.65 | 1 | 25.0% |
| HBV DNA 2000 – 20000, ALT <ULN & APRI < 0.65 | 2 | 50.0% |
| HBV DNA >20000, ALT <ULN & APRI < 0.65 | 1 | 25.0% |
| ART for HIV/HBV co-infection | 8 | 66.7% |
| TLD | 6 | 75.0% |
| TLD + AZT | 1 | 12.5% |
| ABC, 3TC, DTG, TAF | 1 | 12.5% |
ABC: abacavir; AFP: alpha fetoprotein; APRI: aspartate aminotransferase to platelet ratio index; ART: antiretroviral therapy; AZT: zidovudine; DTG: dolutegravir; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HBV DNA: HBV deoxyribonucleic acid; TAF: tenofovir alafenamide; TLD: tenofovir disoproxil, lamivudine, dolutegravir; ULN: upper limit of normal; 3TC: lamivudine.